Protecting the Brain, From the Heart: Safely Mitigating the Consequences of Thrombosis in Intracerebral Hemorrhage Survivors With Atrial Fibrillation.
Laurent PuyRachel FormanCharlotte CordonnierKevin N ShethPublished in: Stroke (2022)
Optimal antithrombotic management after intracerebral hemorrhage remains one of the central unresolved issues for patients who survive, especially for those patients with atrial fibrillation. Given the observational nature of the studies regarding anticoagulation resumption after intracerebral hemorrhage, there is uncertainty regarding resumption of oral anticoagulation therapy and its timing. There is limited high-quality evidence to guide clinical practice, leading to significant practice variation and uncertainty for patients and providers. Here, we aim to provide the key elements to guide clinicians in their individual decision: whether or not to start or resume anticoagulation in patients with a history of intracerebral hemorrhage.
Keyphrases
- atrial fibrillation
- brain injury
- oral anticoagulants
- catheter ablation
- left atrial
- end stage renal disease
- left atrial appendage
- direct oral anticoagulants
- clinical practice
- heart failure
- venous thromboembolism
- ejection fraction
- chronic kidney disease
- newly diagnosed
- healthcare
- percutaneous coronary intervention
- primary care
- peritoneal dialysis
- palliative care
- stem cells
- quality improvement
- white matter
- coronary artery disease
- acute coronary syndrome
- cerebral ischemia
- resting state
- cross sectional
- decision making
- left ventricular